Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035

Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06c. Epub 2017 Apr 18.
No abstract available

Publication types

  • Published Erratum